The risk and prevention of tuberculosa: Screening strategies to detect latent tuberculosis among rheumatoid arthritis patients who use biologic therapy

International Journal of Advances in Rheumatology

Volumn 8, Issue 2, 2010, Pages 43-52

  Winthrop, Kevin L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79958850753     PISSN: 1478856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Forestier J. Rheumatoid arthritis and its treatment with gold salts - results of six years experience. J lob Clin Med 1935;20. 827-40.
2. Wallis RS, Broder MS, Wong JY et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5. (Pubitemid 38608568)
3. Wolfe F, Michaud K, Anderson J et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9. (Pubitemid 38198820)
4. Winthrop KL, Chiller T. Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol 2009;5:405-10.
5. Jrck SS, Lteberman ES, Rahman MU et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55:19-26. (Pubitemid 43235123)
6. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Not Gin Pract Rheumatol 2006, 2:602-10. (Pubitemid 44650948)
7. Winthrop KL, Yamashita S, Beekmann SE et al.; Infectious Diseases Society of America Emerging Infections Network. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008;46:1738-40. (Pubitemid 351706773)
8. Bigbee CL, Gonchoroff DG, Vratsonos G et al. Abatacept treatment does not exacerbate chronic Mycobacterium fubereu/os/s infection in mice. Arthritis Rheum 2007;56:2557-65. (Pubitemid 47237274)
9. ACTEMRA (tocilizumab) prescribing information. Available from: www.gene.com/gene/products/information/actemra/pdf/pi.pdf. Accessed June 2010.
10. St Clair EW, Van Der Heijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43. (Pubitemid 39488667)
11. Askling J, Fored CM, Brandt L et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-92. (Pubitemid 40994319)
12. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72. (Pubitemid 40852885)
13. Tubach F, Salmon D, Ravaud P et al.; Research Axed on Tolerance of Biofherapies Registry. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-94.
14. Dixon WG, Hyrich KL, Watson KD et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologies Register (BSRBR). Ann Rheum Ois 2010;69:522-8.
15. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crrf Care Med 2000;161(4 Pt 2):S221-47.
16. Ponce De Leon D, Acevedo-Vasquez E, Sanchez-Torres A. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Ois 2005, 64:1360-1. (Pubitemid 41206259)
17. Tissot F, Zanetti G, Francioli P et al. influence of baciffe Calmefte-Guerin vaccination on size of tuberculin skin test reaction: to what size? Clin infect Dis 2005, 40:211-7. (Pubitemid 40110663)
18. Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the tmmunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004;4:761-76.
19. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008, 8:147-52.
20. Canadian Tuberculosis Committee (CTC). Updated recommendations on interferon gamma release assays for latent tuberculosis infection. An Advisory Committee Statement (ACS). Con Commun Dis Rep 2008;34:1-13.
21. Martin J, Walsh C, Gibbs A et al. Comparison of interferon {gamma} release assays ond conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010;69:181-5.
22. Matulis G, Juni P, Villiger PM et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tubercu/osi's antigen-specific interferon gamma assay. Ann Rheum Dis 2008, 67:84-90.
23. Ponce De Leon D, Acevedo-Vasquez E, Alvizuri S et al. Comparison of an interferongamma assay with tuberculin skin testing for detection of tuberculosis (TBJ infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008;35:776-81. (Pubitemid 351747116)
24. Cobanoglu N, Ozceltk U, Kalyoncu U et al. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. Inf J Tuberc Lung Dis 2007;11:1177-82. (Pubitemid 350146297)
25. Vassilopoulos D, Stamoulis N, Hadziyannis E et al. Usefulnes of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for antitumor necrosis factor treatment. J Rheumatol 2008;35:1271-6. (Pubitemid 352000770)
26. Bartalesi F, Victdominl S, Goletti D et al. Quant! FE RON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases, tur Respir J 2009;33:586-93.
27. Behar SM, Shin DS, Maier A et al. Use of the T-SPOT. TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. J Rheumatol 2009;36:546-57.
28. Bocchino M, Matarese A, Bellofiore B et al. Performance of two commercial blood IFN-gammo release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Chn Microbiol Infect Dis 2008;27:907-13.
29. British Thoracic Society Standards of Care, Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5.
30. Winthrop KL, Siegel JN, Jereb J et al. Tuberculosis associated with therapy against tumor necrosis factor afpha. Arthritis Rheum 2005;52:2968-74. (Pubitemid 41447075)
31. Saag KG, Teng GG, Patkar NM et al.; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. (Pubitemid 351847559)
32. Bennett DE, Courval JM, Onorato I et al. Prevalence of tuberculosis infection in the United States population: the national health 6nd hutrition examination survey, 1999-2000. Am J Respir Crit Care Med 2008;177:348-55. (Pubitemid 351198380)
33. Piana F, Codecasa LR, Cavallerio P et al. Use of a T-cell-bosed test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006, 28. 31-4. (Pubitemid 44914257)
34. Soborg B, Ruhwald M, Hetland ML et al. Comparison of screening procedures for Mycobacterium fubercu/osrs infection among patients with inflammatory diseases. J Rheumatol 2009;36:1876-84.
35. Murakami S, Tafeeno M, Cirino Y, et al. Screening of tuberculosis by inferferon-famma assay before biologic therapy for rheumatoid arthritis. Tuberculosis (Edi'nb) 2009;89:136-41.
36. Hamdi H, Mariette X, Godot V et al.; RATIO (Recherche sur Antî-TNF et Infections Opportunistes) Study Group. Inhibition of onti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006;8. R114.
37. Park JH, Seo GY, Lee JS et al. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 2009;36:2158-63.
38. Beglinger C, Dudler J, Mottet C et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007;137:620-2.
39. Diel R, Hauer B, Loddenkemper R et al. Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Z Rheumatol 2009;68:411-6.
40. Test de Detection de la production d'interferon pour le diagnostic des infections tuberculeuses. Haute Autorite de Sante, December 2006. Available from: http://www.hassante.fr/portail/upload/docs/application/pdf/synthese- detedion-dejinterferon-gamma.pdf. Accessed April 19, 2010.
41. Mazurek GH, Jereb J, Lobue P et al.; Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC). Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005, 54:49-55.